ES2553742T3 - Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina - Google Patents
Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina Download PDFInfo
- Publication number
- ES2553742T3 ES2553742T3 ES11746176.4T ES11746176T ES2553742T3 ES 2553742 T3 ES2553742 T3 ES 2553742T3 ES 11746176 T ES11746176 T ES 11746176T ES 2553742 T3 ES2553742 T3 ES 2553742T3
- Authority
- ES
- Spain
- Prior art keywords
- dosage form
- pharmaceutical dosage
- fluor
- pyran
- spiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Forma de dosificación farmacéutica para su uso en el tratamiento del dolor que contiene un agente farmacológicamente activo de acuerdo con la fórmula general (I)**Fórmula** donde R es -H o -CH3, o una sal fisiológicamente aceptable del mismo, y una formulación autoemulsionante; administrándose la forma de dosificación farmacéutica dos veces al día, una vez al día o con menos frecuencia.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37063410P | 2010-08-04 | 2010-08-04 | |
US370634P | 2010-08-04 | ||
EP10008115 | 2010-08-04 | ||
EP10008115 | 2010-08-04 | ||
PCT/EP2011/003918 WO2012016703A2 (en) | 2010-08-04 | 2011-08-04 | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2553742T3 true ES2553742T3 (es) | 2015-12-11 |
Family
ID=43446583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11746176.4T Active ES2553742T3 (es) | 2010-08-04 | 2011-08-04 | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP2600838B1 (es) |
JP (1) | JP5792301B2 (es) |
KR (1) | KR101788535B1 (es) |
CN (1) | CN103153282B (es) |
AR (1) | AR082559A1 (es) |
AU (1) | AU2011287873B2 (es) |
BR (1) | BR112013004055A2 (es) |
CA (1) | CA2802767C (es) |
CL (1) | CL2012003584A1 (es) |
CO (1) | CO6640316A2 (es) |
DK (1) | DK2600838T3 (es) |
EC (1) | ECSP13012421A (es) |
ES (1) | ES2553742T3 (es) |
HK (1) | HK1183610A1 (es) |
HR (1) | HRP20151289T1 (es) |
HU (1) | HUE025322T2 (es) |
IL (1) | IL223881A (es) |
MX (1) | MX2013000980A (es) |
NZ (1) | NZ604662A (es) |
PE (1) | PE20131108A1 (es) |
PL (1) | PL2600838T3 (es) |
PT (1) | PT2600838E (es) |
RS (1) | RS54438B1 (es) |
RU (1) | RU2589830C2 (es) |
SI (1) | SI2600838T1 (es) |
TW (1) | TWI522360B (es) |
WO (1) | WO2012016703A2 (es) |
ZA (1) | ZA201209501B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5792299B2 (ja) | 2010-08-04 | 2015-10-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 神経因性疼痛の治療のための6’−フルオロ−(N−メチル−又はN,N−ジメチル−)−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンを含む医薬剤形 |
CN106432256B (zh) * | 2011-12-12 | 2019-08-09 | 格吕伦塔尔有限公司 | 盐酸盐的固体形式 |
TWI567078B (zh) * | 2011-12-12 | 2017-01-21 | 歌林達有限公司 | (1r,4r)-6’-氟-(N,N-二甲基)-4-苯基-4’,9’-二氫-3’H-螺-[環己烷-1,1’-吡喃並-[3,4,b]吲哚]-4-胺及硫酸之固體形式 |
US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
US9345689B2 (en) * | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
US9308196B2 (en) * | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
US9320729B2 (en) * | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
US8912226B2 (en) * | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
US20130310435A1 (en) * | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および/または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
US20180021304A1 (en) | 2015-02-02 | 2018-01-25 | Ratiopharm Gmbh | Composition comprising cebranopadol in a dissolved form |
MX2018010367A (es) | 2016-02-29 | 2018-12-10 | Guenenthal Gmbh | Titulacion de cebranopadol. |
EP3613747A1 (en) * | 2018-08-24 | 2020-02-26 | Grünenthal GmbH | Crystalline forms of trans-6'-fluoro-n-methyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine |
RU2765946C1 (ru) * | 2021-03-11 | 2022-02-07 | Графт Полимер Айпи Лимитед | Система доставки сверхнасыщаемых самонаноэмульгирующихся лекарственных средств (SNEDDS) для слаборастворимых в воде фармацевтических композиций и способ ее приготовления |
WO2024129782A1 (en) | 2022-12-12 | 2024-06-20 | Park Therapeutics, Inc. | Regimens and compositions useful for alleviating pain |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003500368A (ja) * | 1999-05-24 | 2003-01-07 | ソーナス ファーマシューティカルス,インコーポレイテッド | 溶解度が不十分な薬剤のためのエマルジョンビヒクル |
KR100441167B1 (ko) * | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | 마이크로에멀젼 예비 농축액 조성물 |
DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
JP2009514890A (ja) * | 2005-11-07 | 2009-04-09 | マーティ・ファーマシューティカルズ・インク | テトラヒドロカンナビノールの改良された送達 |
DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
-
2011
- 2011-08-04 ES ES11746176.4T patent/ES2553742T3/es active Active
- 2011-08-04 TW TW100127684A patent/TWI522360B/zh not_active IP Right Cessation
- 2011-08-04 DK DK11746176.4T patent/DK2600838T3/en active
- 2011-08-04 CA CA2802767A patent/CA2802767C/en not_active Expired - Fee Related
- 2011-08-04 JP JP2013522138A patent/JP5792301B2/ja not_active Expired - Fee Related
- 2011-08-04 AR ARP110102819A patent/AR082559A1/es not_active Application Discontinuation
- 2011-08-04 RS RS20150822A patent/RS54438B1/en unknown
- 2011-08-04 KR KR1020137005289A patent/KR101788535B1/ko active IP Right Grant
- 2011-08-04 CN CN201180038232.0A patent/CN103153282B/zh not_active Expired - Fee Related
- 2011-08-04 BR BR112013004055A patent/BR112013004055A2/pt not_active IP Right Cessation
- 2011-08-04 RU RU2013109136/15A patent/RU2589830C2/ru not_active IP Right Cessation
- 2011-08-04 NZ NZ604662A patent/NZ604662A/en not_active IP Right Cessation
- 2011-08-04 EP EP11746176.4A patent/EP2600838B1/en active Active
- 2011-08-04 PT PT117461764T patent/PT2600838E/pt unknown
- 2011-08-04 AU AU2011287873A patent/AU2011287873B2/en not_active Ceased
- 2011-08-04 PE PE2013000191A patent/PE20131108A1/es not_active Application Discontinuation
- 2011-08-04 PL PL11746176T patent/PL2600838T3/pl unknown
- 2011-08-04 SI SI201130652T patent/SI2600838T1/sl unknown
- 2011-08-04 WO PCT/EP2011/003918 patent/WO2012016703A2/en active Application Filing
- 2011-08-04 MX MX2013000980A patent/MX2013000980A/es active IP Right Grant
- 2011-08-04 HU HUE11746176A patent/HUE025322T2/en unknown
-
2012
- 2012-12-13 ZA ZA2012/09501A patent/ZA201209501B/en unknown
- 2012-12-19 CL CL2012003584A patent/CL2012003584A1/es unknown
- 2012-12-19 CO CO12230452A patent/CO6640316A2/es not_active Application Discontinuation
- 2012-12-25 IL IL223881A patent/IL223881A/en active IP Right Grant
-
2013
- 2013-02-04 EC ECSP13012421 patent/ECSP13012421A/es unknown
- 2013-08-16 HK HK13109588.4A patent/HK1183610A1/xx not_active IP Right Cessation
-
2015
- 2015-11-27 HR HRP20151289TT patent/HRP20151289T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2553742T3 (es) | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina | |
ECSP13012423A (es) | FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 6'-FLUORO-(N-METIL- O N,N-DIMETIL)-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA PARA EL TRATAMIENTO DE DOLOR NEUROPATICO | |
CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
EP2444072A3 (en) | Non-mucoadhesive film dosage forms | |
AR068816A1 (es) | Composiciones de brimonidina mejorada para el tratamiento del eritema | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
CO2021000174A2 (es) | Composiciones tópicas para el alivio del dolor | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
AR052047A1 (es) | Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias | |
PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
NI201100154A (es) | Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis | |
BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
EA200601901A1 (ru) | Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием | |
AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
JP2011500589A5 (es) | ||
AR065582A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
UY31826A (es) | Compuesto peptídico y su uso | |
AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
RS50693B (sr) | Stabilni farmaceutski gel diklofenak natrijuma | |
ECSP11010941A (es) | Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual | |
AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno |